An overview of select cannabis use and supply indicators pre- and post-legalization in Canada

Abstract

Background Canada implemented the legalization and regulation of non-medical cannabis use, production and sale in 2018 aiming to improve public health and safety. While outcomes from legalization reforms in other jurisdictions mostly rely on US-based data have been assessed to be mixed, Canadian data are only emerging. We compiled select population-level data on key indicators to gauge initial developments from pre- to post-legalization of cannabis in Canada. Methods We examined indicators data focusing on the following topics: prevalence of cannabis use, frequency of use, methods/products of consumption, driving after cannabis use, and cannabis sourcing. Indicator data were obtained mostly from national and some provincial population surveys. Prevalence or percentages for the indicators pre- and post-legalization (e.g., 2017- 2020), including confidence intervals were reported, with changes noted, as available in and indicated by the data sources. Results Data suggested selected increases in cannabis use prevalence, mostly among mid- and older- but possibly also younger (e.g., under legal use age) users. Frequency of use and driving after cannabis use among active users do not appear to have changed. Methods of cannabis use show diversifying trends, with decreases in smoking and increases in alternatives use modes (e.g., edibles, vaping). There is a clearly increasing trend towards accessing cannabis from legal sources among adults, while under-legal-use-age youth do not appear to experience heightened barriers to obtaining cannabis in legalization contexts. Conclusions Preliminary indicators on cannabis legalization in Canada show a mixed picture, some similar to US-based developments. While some use increases are observed, these do not necessarily represent indications of increases in cannabis-related harm, also since key (e.g., hospitalization or injury) data are lacking to date. There is a gradual embracing of legal supply sources of cannabis among users, which can be expected to serve public health and safety objectives. At the same time, cannabis use and access among under-age users as a principally vulnerable group do not appear to be hindered or reduced by legalization.

Cannabis Vaping Among Youth and Young Adults: a Scoping Review

“…Canada legalized recreational marijuana use for adults in 2018. One study reinforced that legalization does not appear to strengthen barriers to obtaining cannabis for underage youth [ 55 ]. Increases in multimodal use of cannabis (e.g., smoking, vaping, and/or ingesting) among underage youth were observed after legislation was passed [ 54 , 56 ].…”

Cannabis use and risks of respiratory and all-cause morbidity and mortality: a population-based, data-linkage, cohort study

“…We had access to cannabis use data only from the time prior to its decriminalisation in Canada (ie, October 2018). Cannabis use has increased in Canada following its decriminalisation (mostly among middle-aged and older adults), 41 potentially affecting both the frequency and nature of related adverse events, but we were unable to perform an analysis before and after decriminalisation. We were also unable to adjust for possible secondhand cannabis smoke exposure among control individuals, as such data were not available to us.…”

Considerations for Cannabinoids in Perioperative Care by Anesthesiologists

“…Marijuana remains the most common illicit substance in the USA. Marijuana consumption increased by 6.5% from 2002 to 2019, especially in states that legalized the use of marijuana [16,17]. Neocannabinoids, synthetic analogs of naturally occurring cannabinoids, are used by individuals between 20 and 40 years old, especially in cases of fatal overdose [42,43].…”

“…However, they are of increased interest because they possess several unique pharmacological properties [1,2,4,[11][12][13][14][15]. These pharmacological potentials have been utilized in several ways, with recreational use comprising the majority of cannabinoid consumption [2,4,12,16,17]. FDA-approved indications for cannabinoid treatment include seizures, nausea, cancer pain, and certain neurological conditions [18][19][20].…”